AstraZenecca Bullish trend is still intact
AstraZeneca, the biopharmaceutical company, said that “the Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020"
Share this:
AstraZeneca, the biopharmaceutical company, said that “the Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall."
AstraZeneca recalls joining forces with the British government to support the Oxford University vaccine. It is also working with international organizations, including the WHO, to distribute the vaccine worldwide.
AstraZeneca recalls joining forces with the British government to support the Oxford University vaccine. It is also working with international organizations, including the WHO, to distribute the vaccine worldwide.
From a chartist’s point of view, the stock price remains within a short term bullish channel, supported by the 20-day simple moving average currently at 8,550p. Bollinger bands confirm the bullish trend. However, the Relative Strength Index (RSI, 14) has broken down its overbought area at 70% indicating that a consolidation move could be on the cards. First support threshold is set at 8,522p (Horizontal level + Channel lower boundary).
As long as 8,048 is support, readers may want to take advantage of any pullback as an opportunity to open long positions with 9,000p and 9,600p as targets.
Alternatively, a break below 8,048 would call for a reversal down trend towards 7,300p.
Souce: GAIN Capital, TradingView
AstraZeneca, the biopharmaceutical company, said that “the Company has concluded the first agreements for at least 400 million doses and has secured total manufacturing capacity for one billion doses so far and will begin first deliveries in September 2020. AstraZeneca today received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) for the development, production and delivery of the vaccine, starting in the fall."
AstraZeneca recalls joining forces with the British government to support the Oxford University vaccine. It is also working with international organizations, including the WHO, to distribute the vaccine worldwide.
AstraZeneca recalls joining forces with the British government to support the Oxford University vaccine. It is also working with international organizations, including the WHO, to distribute the vaccine worldwide.
From a chartist’s point of view, the stock price remains within a short term bullish channel, supported by the 20-day simple moving average currently at 8,550p. Bollinger bands confirm the bullish trend. However, the Relative Strength Index (RSI, 14) has broken down its overbought area at 70% indicating that a consolidation move could be on the cards. First support threshold is set at 8,522p (Horizontal level + Channel lower boundary).
As long as 8,048 is support, readers may want to take advantage of any pullback as an opportunity to open long positions with 9,000p and 9,600p as targets.
Alternatively, a break below 8,048 would call for a reversal down trend towards 7,300p.
Souce: GAIN Capital, TradingView
Latest market news
The complete CFD trading experience
Award-winning platforms, competitive spreads, low commissions and dedicated support.
We live and breathe the markets and are dedicated to helping traders realise their ambitions as we continue to set the industry bar.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
S&P 500, Nasdaq, Dow Forecast: Rising Yields Test Rally Ahead of Nvidia, Fed 8 22 2026
S&P 500, Nasdaq and Dow test key technical levels as momentum fades, raising the risk of a deeper correction heading into a pivotal week.
Magnificent Seven Earnings Preview: Can Big Tech Reclaim AI Leadership?
The Magnificent Seven enter earnings with far more divided performance than in previous years, as investors increasingly distinguish between companies supplying the AI buildout and those funding it - what does that mean heading into earnings season?
EUR/USD, FTSE 100 Forecast: Two trades to watch 1507
EUR/USD rises after weaker US CPI, PPI up next. FTSE 100 falls as weak China GDP data hits miners.
StoneX Europe Ltd may make third party material available on this website which may contain information included but not limited to the conditions of financial markets. The material is for information purposes only and does not contain, and should not be construed as containing, investment advice and/or investment recommendation and/or an investment research and/or an offer of or solicitation for any transactions in financial instruments; any decision to enter into a specific transaction shall be made by the client following an assessment by him/her of their situation.
StoneX Europe Ltd makes no representation or warranty and assumes no liability as to the accuracy or completeness of the information provided, nor any loss arising from any investment based on a recommendation, forecast or other information supplied. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. We are not under any obligation to update any such material. Any opinion made may be personal to the author and may not reflect the opinion of StoneX Europe Ltd.